᪂つヨ㦂ἲᥦ᱌᭩             ᖹᡂ  ᖺ  ᭶  ᪥                                  1R 

⓶⭵ឤసᛶヨ㦂௦᭰ἲゅ໬⣽⬊ᰴ࣏࣮ࣞࢱ࣮࢔ࢵࢭ࢖࡟㛵ࡍࡿᥦ᱌ ᖹᡂ 27 ᖺ 4 ᭶ 23 ᪥࡟ᮾிࠊᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ࡟࡚㛤ദࡉࢀࡓ᪂つヨ㦂ἲホ౯఍㆟㸦㏻⛠㸸JaCVAM ホ౯఍㆟㸧࡟࠾࠸࡚௨ୗࡢᥦ᱌ࡀ࡞ࡉࢀࡓࠋ  ᥦ᱌ෆᐜ㸸 ゅ໬⣽⬊ᰴ࣏࣮ࣞࢱ࣮࢔ࢵࢭ࢖࡛㝧ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࠊࡑࡢ໬Ꮫ≀㉁ࢆᙉ࠸
ឤసᛶ≀㉁࡛࠶ࡿ GHS(Globally Harmonized System of Classification and Labelling ofChemicals)༊ศ㸯࡟ศ㢮ࡍࡿࡇ࡜ࡣ⾜ᨻୖྍ⬟࡛࠶ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊ⛥࡟ഇ㝧ᛶࡢ⤖ᯝࡀ⏕ࡌࡿࡇ࡜࡟␃ពࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ୍᪉ࠊᮏヨ㦂ἲ࡛㝜ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࠊࡑࡢ໬Ꮫ≀㉁ࡢ⓶⭵ឤసᛶࡣഇ㝜ᛶࡢྍ⬟ᛶࡀ࠶ࡾࠊᮏヨ㦂ἲ༢⊂࡛ࡑࡢ⓶⭵ឤసᛶࢆุᐃࡍࡿࡇ࡜ࡣ㞴ࡋ࠸ࠋᮏヨ㦂ἲࡣࠊࡑࡢ≉ᛶࢆ༑ศ࡟⌮ゎࡋࡓୖ࡛ࠊIATA(Integrated Approaches to Testing and Assessment) ࢆᵓᡂࡍࡿࡑࡢ௚ࡢ᝟ሗ※࡜⤌ࡳྜࢃࡏ࡚㐺ษ࡟ホ౯ࡍࡿࡇ࡜ࡀࠊ⾜ᨻⓗ࡞ཷࡅධࢀ࡟ᚲせ࡛࠶ࡿ࡜⪃࠼ࡿࠋࡇࡢᥦ᱌᭩ࡣࠊOECD TG 442D; In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method࠾ࡼࡧ
JRC Scientific and Policy report,

EURL ECVAM Recommendation on the KeratinoSensTM assay forskin sensitisation testingࢆࡶ࡜࡟ࠊ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍࡟ࡼࡾࡲ࡜ࡵࡽࢀࡓᩥ᭩ࢆ⏝࠸࡚ࠊJaCVAMホ౯఍㆟ࡀホ౯࠾ࡼࡧ᳨ウࡋࡓ⤖ᯝࠊࡑࡢ᭷⏝ᛶࡀ☜ㄆࡉࢀࡓࡇ࡜࠿ࡽసᡂࡉࢀࡓࠋ ௨ୖࡢ⌮⏤࡟ࡼࡾࠊ⾜ᨻᙜᒁࡢᏳ඲ᛶホ౯᪉ἲ࡜ࡋ࡚⓶⭵ឤసᛶヨ㦂௦᭰ἲ ࣌ࣉࢳࢻ⤖ྜᛶ
ヨ㦂ࡢ౑⏝ࢆᥦ᱌ࡍࡿࡶࡢ࡛࠶ࡿࠋ ኱㔝Ὀ㞝                      すᕝ⛅ెJaCVAM ホ౯఍㆟ ㆟㛗               JaCVAM 㐠Ⴀጤဨ఍ ጤဨ㛗i

-D&9$0 ホ౯఍㆟኱㔝Ὀ㞝㸦㐠Ⴀጤဨ఍᥎⸀㸧㸸ᗙ㛗஬༑ᔒⰋ᫂㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ ⏕ά⾨⏕໬Ꮫ㒊㸧㣤ሯᑦᩥ㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧㔠Ꮚ࿴ᘯ㸦᪥ᮏ໬Ꮫᕤᴗ༠఍㸧⠛⏣࿴ಇ㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧ᮡᒣ┿⌮Ꮚ㸦᪥ᮏ໬⢝ရᕤᴗ㐃ྜ఍㸧㇂ᕝᾈᏊ㸦᪥ᮏື≀ᐇ㦂௦᭰ἲᏛ఍㸧すᕝ⛅ె㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮㸧∾ ᰤ஧㸦᪥ᮏච␿ẘᛶᏛ఍㸧᳃⏣ ೺㸦᪥ᮏ⎔ቃኚ␗ཎᏛ఍㸧ᒣ⏣㝯ᚿ㸦⊂❧⾜ᨻἲே 〇ရホ౯ᢏ⾡ᇶ┙ᶵᵓ㸧ᶓ㛵༤㞝㸦᪥ᮏ⓶⭵࢔ࣞࣝࢠ࣮࣭᥋ゐ⓶⭵⅖Ꮫ఍㸧ྜྷ⏣Ṋ⨾㸦᪥ᮏẘᛶᏛ఍㸧ྜྷ⏣ ⥳㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⑓⌮㒊㸧ྜྷᮧ ຌ㸦ᗙ㛗᥎⸀㸧Ώ㒊୍ே㸦᪥ᮏ〇⸆ᕤᴗ༠఍㸧                  ௵ᮇ㸸ᖹᡂ 26 ᖺ 4 ᭶ 1 ᪥㹼ᖹᡂ 28 ᖺ 3 ᭶ 31 ᪥ii

-D&9$0 㐠Ⴀጤဨ఍すᕝ⛅ె㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮㸧㸸ጤဨ㛗ᕝす ᚭ  㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ㸧᳜ᮧᒎ⏕㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ᑂᰝ⟶⌮ㄢ㸧ᑠᕝஂ⨾Ꮚ 㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⑓⌮㒊㸧Ⳣ㔝 ⣧㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ẘᛶ㒊㸧಴ᣢ᠇㊰㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ໬Ꮫ≀㉁Ᏻ඲ᑐ⟇ᐊ㸧㛵㔝♸Ꮚ㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⸆⌮㒊㸧㧗ᮌ⠜ஓ㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ẘᛶ㒊 ື≀⟶⌮ᐊ㸧᮰㔝ṇ᫂㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ໬Ꮫ≀㉁Ᏻ඲ᑐ⟇ᐊ㸧୰ᮧ㧗ᩄ㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧᪥⏣ ඘㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ໬Ꮫ≀㉁Ᏻ඲ᑐ⟇ᐊ㸧ᗈ℩᫂ᙪ  㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ Ᏻ඲ᛶணホ౯㒊㸧ᮏ㛫ṇ඘㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ኚ␗㑇ఏ㒊㸧ᑠᓥ ⫕㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ Ᏻ඲ᛶணホ౯㒊 ➨஧ᐊ㸧㸸஦ົᒁ

iii

iv

JaCVAM statement on ARE-Nrf2 Luciferase Test Method assay for skinsensitisation testing
At a meeting held on 23 April 2015 at the National Institute of Health Sciences (NIHS) inTokyo, Japan, the Japanese Center for the Validation of Alternative Methods (JaCVAM)
Regulatory Acceptance Board unanimously endorsed the following statement:  Proposal: When using the ARE-Nrf2 Luciferase Test Method in a regulatory context, it isreasonable for substances that give positive results to be classified as a strong
sensitiser, i.e., a Category 1 substance under the Globally Harmonized System ofClassification and Labelling of Chemicals (GHS). It is also necessary, however,to bear in mind that this assay occasionally yields false positive results forcertain substances. Conversely, it is quite possible that the ARE-Nrf2 Luciferase
Test Method will yield false negative results for some chemicals, which meansthat it would be unreasonable to use it as a standalone test for assessing skinsensitisation potency. We therefore conclude that the use of the ARE-Nrf2
Luciferase Test Method in a regulatory context requires a thoroughunderstanding of the assay’s strengths and weaknesses as a prerequisite to its
application within an integrated approach to testing and assessment (IATA) thatwill also take into account information from other sources.
This statement was prepared following a review of OECD TG 442D “In Vitro Skin
Sensitisation: ARE-Nrf2 Luciferase Test Method” as well as a JRC Scientific and Policy
report “EURL ECVAM Recommendation on the KeratinoSensTM assay for skin sensitisationtesting”. The JaCVAM Regulatory Acceptance Board acknowledges that the results of thisreview as well as of a study of materials prepared by the JaCVAM Editorial Committee
indicate that this assay is useful in a regulatory context.
Based on the above, we propose that regulatory agencies performing safety assessment of skinsensitisation potency consider using the ARE-Nrf2 Luciferase Test Method as an alternative to
testing with laboratory animals.

Yasuo Ohno
Chairperson
JaCVAM Regulatory Acceptance BoardAkiyoshi Nishikawa
Chairperson
JaCVAM Steering Committee20 August 2015v

The JaCVAM Regulatory Acceptance Board was established by the JaCVAM SteeringCommittee, and is composed of nominees from the industry and academia.
This statement was endorsed by the following members of the JaCVAM Regulatory
Acceptance Board:

Mr. Yasuo Ohno (nominee by JaCVAM Steering Committee) : Chairperson
Mr. Naofumi Iizuka (Pharmaceuticals and Medical Devices Agency)
Mr. Yoshiaki Ikarashi (National Institute of Health Sciences: NIHS)
Mr. Kazuhiro Kaneko (Japan Chemical Industry Association)
Mr. Eiji Maki (Japanese Society of Immunotoxicology)
Mr. Takeshi Morita (Japanese Environmental Mutagen Society)
Mr. Akiyoshi Nishikawa (NIHS)
Mr. Kazutoshi Shinoda (Pharmaceuticals and Medical Devices Agency)
Ms. Mariko Sugiyama (Japan Cosmetic Industry Association)
Ms. Koko Tanigawa (Japanese Society for Alternatives to Animal Experiments)
Mr. Takashi Yamada (National Institute of Technology and Evaluation)
Mr. Hiroo Yokozeki (Japanese Society for Dermatoallergology and Contact Dermatitis)
Ms. Midori Yoshida (NIHS)
Mr. Takemi Yoshida (Japanese Society of Toxicology)
Mr. Isao Yoshimura (nominee by Chairperson)
Mr. Kazuto Watanabe (Japan Pharmaceutical Manufacturers Association)

Term: From 1st April 2014 to 31st March 2016vi

This statement was endorsed by the following members of the JaCVAM steering Committee
after receiving the report from JaCVAM Regulatory Acceptance Board:

Mr. Akiyoshi Nishikawa (BSRC, NIHS): Chairperson
Mr. Toru Kawanishi (NIHS)
Mr. Mitsuru Hida (Ministry of Health, Labour and Welfare)
Mr. Akihiko Hirose (Division of Risk Assessment, BSRC, NIHS)
Mr. Masamitsu Honma (Division of Genetics and Mutagenesis, BSRC, NIHS)
Mr. Jun Kanno (Division of Cellular and Molecular Toxicology, BSRC, NIHS)
Mr. Kenji Kuramochi (Ministry of Health, Labour and Welfare)
Mr. Takatoshi Nakamura (Pharmaceutical & Medical Devices Agency)
Ms. Kumiko Ogawa (Division of Pathology, BSRC, NIHS)
Ms. Yuko Sekino (Division of Pharmacology, BSRC, NIHS)
Mr. Kazutoshi Shinoda (Pharmaceuticals and Medical Devices Agency)
Mr. Atsuya Takagi (Animal Management Section of the Division of Cellular andMolecular Toxicology, BSRC, NIHS)
Mr. Masaaki Tsukano (Ministry of Health, Labour and Welfare)
Mr. Nobuo Uemura (Ministry of Health, Labour and Welfare)Mr. Hajime Kojima (Section for the Evaluation of Novel Methods, Division of Risk
Assessment, BSRC, NIHS): Secretaryvii